nioMérieux Customer:	Microbiology Chart Report			Printed 9,1,	20227:19:31 AM CS
Patient Name: Location: Lab ID: 19					Patient ID: e1 Physiciar Isolate Number:
Organism Quantity: Selected Organism : Escherichi Source: Urine	a coli				Collected
Comments:					
Identification Information		Analysis Time:	3.85 hours	Status:	Final
Selected Organism		99% Probability Bionumber:	Escherichia coli 0405610550504611		
ID Analysis Messages					
Susceptibility Information	Analysis T	ime: 10.70 hours		Status:	Final
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation
ESBL.	NEG	-	Amikacin	32	ı
Ampicillin	>= 32	R	Gentamicin	>= 16	R
Piperucillin/Tazobactam	>= 128	R	Ciprofloxacin	>= 4	R
Cefazolin	>= 64	R	+Gemifloxacin		R
Cefoxitin	>= 64	R	Levofloxacin	>= 8	R
Ceftazidime	>= 64	R	+Moxifloxacin		R
Ceftriaxone	>= 64	R	Tigecycline	<= 0.5	S
Cefepime	>= 64	R	Nitrofurantoin	128	R
Imipenem	>= 16	R	Trimethoprim/ Sulfamethoxazole	>= 320	R
AES Findings					
Confidence: Cons	istent				
Confidence: Cons	i attiti				

## Supplementary Fig.1. Identification report of E. coli by VITEK 2 device

bioMérieux Customer: Patient Name: Location: Lab ID: 20		Microbiolo	gy Chart Report	Printed 9,	1, 2022 7:19:33 AM C Patient ID: d Physicia
Organism Quantity:					Isolate Number
Selected Organism : Klebsle	lla pneumonia				
Source: Urine					
					Collected
Comments:					
- Commence					
Susceptibility Information	n Analysis T	ime: 9.00 hours		Status:	Final
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	
ESBL	POS	+	Amikacia	16	Interpretation
Ampicillin	>= 32	R	Gentamicin	<= 1	•1
Piperucillin/Tazobactam	16	S	Ciprofloxacin	>= 4	S
Cefazolin	>= 64	R	+Gemifloxacin	>= 4	R
Cefoxitin	8	S	Levofloxacin	>= 8	R
Ceftazidime	16	R	+Moxifloxacin	>= 8	R
Ceftriaxone	>= 64	R	Tigecycline	<= 0.5	R
Cefepime	>= 64	R	Nitrofurantoin	<= 16	S
Ertapenem	<= 0.5	S	Trimethoprim/		S
			Sulfamethoxazole	>= 320	R
mipenem	<= 0.25	S			
- AES modified **- User modified	d				
AES Findings					
onfidence: Con	sistent				

## $\textbf{Supplementary Fig.2.} \ \ \textbf{Identification report of} \ \textit{Klebsiella Sp} \ \textbf{by VITEK 2 device}$

bioMérieux Customer:		Microbiolog	y Chart Report	Deintari O I	, 2022 7:19:36 AM CS
Patient Name: Location: Lab ID: 24			g chart Report	France 9,1	Patient ID: d2 Physicia
Organism Quantity: Selected Organism: Pseudon	nonas aerugino	osa			Isolate Number:
Source: Swab					Collected:
Comments:					
Supportibility I. C.					
Susceptibility Information	n Analysis T	ime: 9.98 hours		Status:	Final
Antimicrobial	MIC		Antimicrobial	1 100000	1
Antimicrobial Piperacillin/Tazobactam		Interpretation S	Antimicrobial Amikacin	MIC	Interpretation
Antimicrobial  Piperacillin/Tazobactam  Cefazolin	MIC	Interpretation	Amikacin	MIC 4	Interpretation S
Antimicrobial Piperacillin/Tazobactam Cefazolin Ceftazidime	MIC 8	Interpretation S	Amikacin Gentamicin	MIC 4 4	Interpretation S S
Antimicrobial Piperacillin/Tazobactam Cefazolin Ceftazidime Cefepime	MIC 8 >= 64	Interpretation S R	Amikacin	MIC 4	Interpretation S S S
Susceptibility Information Antimicrobial Piperacillin/Tazobactam Cefazolin Cefazolime Cefepime Imipenem	MIC 8 >= 64 4	Interpretation S R S	Amikacin Gentamicin Ciprofloxacin	MIC 4 4	Interpretation S S
Antimicrobial Piperacillin/Tazobactam Cefazolin Ceftazidime Cefepime	MIC 8 >= 64 4 4	Interpretation S R S S	Amikacin Gentamicin Ciprofloxacin Levofloxacin	MIC 4 4 <= 0.25	Interpretation S S S S S

bioMérieux Customer:	Microbiology Chart Report				Printed 9 ,1, 2022 7:21:08 AM C		
Patient Nume: Location: Lab ID: 3			Patient ID: Physici Isolate Number				
Organism Quantity: Selected Organism : Staphyloc Source: Unknown	occus nureus				Collected		
Comments:							
Susceptibility Information	Analysis T	ime: 10.45 hours		Status:	Final		
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation		
Cefoxitin Screen	POS	+	Teicoplanin	<= 0.5	S		
Benzy Ipenicillin	>= 0.5	R	Vancomycin	1	S		
Oxacillin	>= 4	R	Tetracycline	>= 16	R		
Gentamicin	8	1	Tigecycline	<= 0.12	S		
Tobramycin	>= 16	R	Fosfomycin				
Levofloxacin	>= 8	R	Nitrofurantoin	32	S		
Moxifloxacin	4	R	Fusidic Acid	>= 32	R		
Inducible Clindamycin Resistance	NEG		Mupirocin				
Erythromycin	>= 8	R	Rifampicin	>= 32	R		
Clindamycin	>= 8	R	Trimethoprim/ Sulfamethoxazole	80	R		
Linezolid	2	S					
AES Findings							
Confidence: Consi	stont						

## Supplementary Fig. 4. Identification report of Staphylococcus aureus by VITEK 2 device


bioMérieux Customer:	Microbiology Chart Report			Printed 9 ,1, 2022 7:21:14 AM CS		
Patient Name: Location: Lab ID: 40				Patient ID; a. Physici Isolate Numbe		
Organism Quantity: Selected Organism : Staphyloc Source: Endocervical swab	occus epidermi	dis			Collected	
Comments:						
Susceptibility Information	Analysis Tim	e: 12.17 hours		Status:	Final	
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation	
Cefoxitin Screen	POS	+	Teicoplanin	<= 0.5	S	
Benzy Ipenicittin	>= 0.5	R	Vancomycin	<= 0.5	S	
Oxacillin	<= 0.25°	*R	Tetracycline	<= 1	S	
Gentamicin	<= 0.5	S	Tigecycline	<= 0.12	S	
Tobramycin	<= 1	S	Fosfomycin			
Levofloxacin	<= 0.12	S	Nitrofurantoin	<= 16	S	
Moxifloxacin	<= 0.25	S	Fusidic Acid	16	R	
Inducible Clindamyeln Resistance	NEG	-	Mupirocin			
Erythromycin	<= 0.25	S	Rifampicin	<= 0.5	S	
Clindamyein	2	1	Trimethoprim/ Sulfamethoxazole	<= 10	S	
Linezolid	2	S		9.12		
AES modified User modified						
AES Findings						

## Supplementary Fig. 5. Identification report of Staphylococcus epidermidis by VITEK 2 device


bioMérieux Customer:	Microbiology Chart Report			Printed 9 ,1	, 2022 7:21:10 AM C
Patient Name: Location: Lab ID: 14					Patient ID: 1 Physici Isolate Numbe
Organism Quantity: Selected Organism : Staphyloc	occus haemo	lyticus			
Source: Urine					Collecte
Comments:					
Identification Information		Analysis Time:	4.80 hours	Status:	Final
Selected Organism		99% Probability Bionumber:	99% Probability Staphylococcus haemolyticus		
ID Analysis Messages					
Susceptibility Information	Analysis T	ime: 8.95 hours		Status:	Final
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation
Cefoxitin Screen	POS	+	Teicoplanin	4	S
Benzylpenicillin	>= 0.5	R	Vancomycin	1	S
Oxacillin	>= 4	R	Tetracycline	2	S
Gentamicin	>= 16	R	Tigecycline	0.5	S
Tobramycin	>= 16	R	Fosfomycin		
Levofloxacin	4	R	Nitrofurantoin	<= 16	S
Moxifloxacin	1		Fusidic Acid	2	R
Inducible Clindamycin Resistance	NEG	-	Mupirocin		
Erythromycin	>= 8	R	Rifampicin	>= 32	R
Clindamycin	<= 0.25	S	Trimethoprim/ Sulfamethoxazole	>= 320	R
Linezolid	2	S			
AES Findings		Mark Spirit			
Confidence: Cons	istent				


Patient Name: Location: Lab ID: 35			gy Chart Report	Printed 9 ,1, 2022 7:19:38 AM C Patient ID: e Physicis			
Organism Quantity: Selected Organism : Proteus m Source: Urine	irabilis	4			Isolate Number		
Comments:					Collected		
Susceptibility Information	Analysis T	Analysis Time: 11.93 hours			Status: Final		
Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretation		
Ampicillin	>= 32	R	Amikacin	16	*1		
Piperacillin/Tazobactam	<= 4	S	Gentamicin	8	1		
Cefazolin	>= 64	R	Ciprofloxacin	>= 4	R		
Cefoxitin	<= 4	S	+Gemifloxacin		R		
Ceftazidime	>= 64	R	Levofloxacin	>= 8	R		
Ceftriaxone	>= 64	R	+Moxifloxacin		R		
Cefepime	>= 64	R	Tigecycline	4	*R		
Ertapenem	<= 0.5	S	Nitrofurantoin	128	R		
Imipenem	4	R	Trimethoprim/ Sulfamethoxazole	>= 320	R		
-= AES modified= User modified							
AES Findings							
Confidence: Consi	stent						

Supplementary Fig.7. Identification report of *Proteus* by VITEK 2 device




Supplementary Fig. 8. Results of physical and biochemical tests for the urine of a person infected with bacteria







Supplementary Fig. 10. Results of physical and biochemical tests for the urine of a person infected with bacteria




Supplementary Fig. 11. Results of physical and biochemical tests for the urine of a person infected with bacteria




Supplementary Fig. 12. Results of physical and biochemical tests for the urine of a person infected with bacteria




Supplementary Fig. 13. Results of physical and biochemical tests for the urine of a person infected with bacteria



Supplementary Fig. 14. Results of physical and biochemical tests for the urine of a person infected with bacteria




Supplementary Fig. 15. Results of physical and biochemical tests for the urine of a person infected with bacteria




Supplementary Fig. 16. Results of physical and biochemical tests for the urine of a person infected with bacteria




A- Staph resistance. saprophyticus for anti-novobiocin.



B- sensitivity staph. epidermidis for antibiotics. C- Sensitive Pseudomonas SP. for antibiotics.



 ${f D.}\ {\it E.}\ {\it coli}\ {\it bacteria}\ {\it sensitivity}\ {\it to}\ {\it antibiotics}.$ 



E. Sensitivity of Klebsiella sp. to antibiotics.

Supplementary Fig. 17. (A-E) Bacterial Suitability to antibiotic